Apparently, those with BRCA2 mutations respond better to PARP inhibitors as compared to the prostate cancer patients with ATM and CHEK2 alterations [132]; nevertheless, the same correlation with higher genomic scarring composite scores has been revealed in the respective DDR gene mutations [148]. This evidence concerns the gene ATM and prostate carcinoma.